No insider purchase over the last 90 days. The latest was filed 25 Aug 2025.
Every trade that managers of Medtronic plc disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector and is based in Ireland, Ireland. It was founded in 1949. 25 insiders have disclosed 57 filings since 18 October 2025.
No insider bought on the market over the period, while 2 insiders filed 2 sales totalling €2.2M. Biggest ticket of the year: €2.1M, sold by Smith Gregory L and made public on 21 November 2025.
With 57 filings in twelve months, the company is more active than the median of 19 filings across the 5,816 companies we follow on the same exchange. Since 2016, the database holds 2 purchases and 17 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 24 April 2026), the company reported revenue of 36.36 bn USD and net income of 4.80 bn USD, with a dividend of 2.84 USD per share.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate Medtronic plc Buy (bullish), based on 25 analysts. Average price target: US$104.40.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended April 2026 · cache
25 of 278 declarations
Medtronic plc is one of the world’s leading medical technology companies and is listed on the NYSE in the United States under the ticker MDT. For French, Belgian, and Swiss investors, it typically fits the profile of a large-cap defensive healthcare name with exposure to long-duration structural drivers such as aging populations, chronic disease prevalence, and the shift toward less invasive procedures. Medtronic traces its origins to a small electrical repair business founded in 1949 in Minneapolis. Today, its operational headquarters remains in Minneapolis, Minnesota, United States, reinforcing its identity as a classic U.S. healthcare industrial champion with a global commercial footprint. ([medtronic.com](https://www.medtronic.com/en-us/our-company/key-facts.html?utm_source=openai))
The company’s business model spans several core medical device franchises, including cardiovascular solutions, cardiac rhythm management, structural heart therapies, vascular therapies, surgical and robotics-enabled care, neuromodulation, spine, and diabetes management. Its product set includes transcatheter aortic valve replacement systems (TAVR), pulsed field ablation (PFA) technologies, pacemakers and implantable cardiac devices, glucose monitoring and insulin delivery systems, as well as surgical instruments and related hospital technologies. This breadth gives Medtronic scale and resilience, but it also means the company must continuously invest in R&D and navigate stringent regulatory, reimbursement, and clinical evidence requirements. ([news.medtronic.com](https://news.medtronic.com/2025-05-21-Medtronic-reports-strong-finish-to-its-fiscal-year-with-its-fourth-quarter-financial-results-announces-dividend-increase?utm_source=openai))
In competitive terms, Medtronic remains a global benchmark in medtech, with a broad installed base across hospitals and physicians, and a meaningful position in both developed and emerging markets. Its scale, clinical relationships, and diversified portfolio are key advantages versus peers such as Boston Scientific, Abbott, and Johnson & Johnson’s medical device businesses. Recent management commentary has emphasized growth engines such as PFA, TAVR, neuromodulation, and spine, which suggests a deliberate shift toward higher-growth and higher-margin categories. ([news.medtronic.com](https://news.medtronic.com/2025-05-21-Medtronic-reports-strong-finish-to-its-fiscal-year-with-its-fourth-quarter-financial-results-announces-dividend-increase?utm_source=openai))
The most important recent strategic development came in May 2025, when Medtronic announced its intent to separate its Diabetes business into a new standalone company, later named MiniMed in June 2025. Management framed the move as a portfolio simplification step that would sharpen Medtronic’s focus on its highest-value franchises while allowing the diabetes unit to pursue its own growth path. Medtronic also reported solid fiscal 2025 results and increased its dividend, which underscores continued cash generation and shareholder-return discipline. ([news.medtronic.com](https://news.medtronic.com/2025-05-21-Medtronic-announces-intent-to-separate-Diabetes-business?utm_source=openai))
Purchases our model currently ranks for the recommendations list.
All recommendationsInsider filings
Over the last 90 days, 22 filings published between 29 July and 15 October 2026: 1 sale for €120k. 21 other filings (not open-market purchases or sales: grants, options, plans, sale notices, block transfers). Largest amounts: KIIL HARRY SKIP (EVP & President Cardiovascular), sales of €120k.
Summary written automatically from public filings, without human review. General information, identical for every reader: it is not investment advice or a recommendation to buy or sell. Investing involves a risk of capital loss. Generated on 17 October 2026 (UTC)
Headquarters: Ireland, Ireland · Founded: 1949 · 86,000 employees (2018) · Wikipedia article
Source: Wikidata (CC0).
| Fiscal year end | Revenue | Net income | Diluted EPS | Dividend per share | Filing |
|---|---|---|---|---|---|
| Apr 2026 | 36.36 bn USD | 4.80 bn USD | 3.73 USD | 2.84 USD | 10-K |
| Apr 2025 | 33.54 bn USD | 4.66 bn USD | 3.61 USD | 2.80 USD | 10-K |
| Apr 2024 | 32.36 bn USD | 3.68 bn USD | 2.76 USD | 2.76 USD | 10-K |
| Apr 2023 | 31.23 bn USD | 3.76 bn USD | 2.82 USD | 2.72 USD | 10-K |
| Apr 2022 | 31.69 bn USD | 5.04 bn USD | 3.73 USD | 2.52 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.